Phreesia (NYSE:PHR) Given “Neutral” Rating at Citigroup

Citigroup reaffirmed their neutral rating on shares of Phreesia (NYSE:PHR) in a research note issued to investors on Tuesday, MarketBeat reports. Citigroup currently has a $10.00 price target on the stock, down from their prior price target of $25.00.

PHR has been the subject of a number of other research reports. Robert W. Baird restated a “neutral” rating and issued a $10.00 target price (down from $25.00) on shares of Phreesia in a research note on Tuesday. DA Davidson dropped their price target on Phreesia from $35.00 to $30.00 and set a “buy” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada initiated coverage on Phreesia in a report on Friday, January 9th. They issued a “moderate buy” rating and a $26.00 price objective on the stock. Needham & Company LLC reduced their price objective on Phreesia from $35.00 to $14.00 and set a “buy” rating for the company in a research note on Tuesday. Finally, Wells Fargo & Company dropped their target price on Phreesia from $30.00 to $25.00 and set an “overweight” rating on the stock in a research report on Thursday, March 26th. Thirteen analysts have rated the stock with a Buy rating, five have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $22.00.

Phreesia Stock Down 27.0%

NYSE:PHR opened at $8.33 on Tuesday. The company has a current ratio of 2.44, a quick ratio of 2.44 and a debt-to-equity ratio of 0.01. Phreesia has a twelve month low of $7.77 and a twelve month high of $32.76. The company has a market cap of $502.28 million, a PE ratio of 277.70 and a beta of 0.67. The company’s 50 day moving average is $12.36 and its two-hundred day moving average is $17.57.

Phreesia (NYSE:PHR) last posted its quarterly earnings results on Monday, March 30th. The company reported $0.02 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.07 by ($0.05). Phreesia had a return on equity of 3.33% and a net margin of 0.48%.The company had revenue of $127.07 million during the quarter, compared to analysts’ expectations of $126.75 million. During the same period in the prior year, the business posted ($0.11) EPS. The company’s quarterly revenue was up 15.9% on a year-over-year basis. Analysts anticipate that Phreesia will post -1.1 EPS for the current year.

Insider Buying and Selling

In other Phreesia news, CFO Balaji Gandhi sold 3,829 shares of the stock in a transaction dated Wednesday, March 25th. The stock was sold at an average price of $11.26, for a total transaction of $43,114.54. Following the sale, the chief financial officer directly owned 146,740 shares of the company’s stock, valued at approximately $1,652,292.40. This trade represents a 2.54% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Linetsky sold 6,038 shares of Phreesia stock in a transaction dated Friday, January 16th. The shares were sold at an average price of $16.36, for a total value of $98,781.68. Following the transaction, the insider owned 223,942 shares of the company’s stock, valued at $3,663,691.12. The trade was a 2.63% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold 70,358 shares of company stock valued at $1,123,569 in the last 90 days. 5.50% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the stock. Vanguard Group Inc. increased its position in shares of Phreesia by 0.7% in the fourth quarter. Vanguard Group Inc. now owns 5,744,326 shares of the company’s stock valued at $97,194,000 after buying an additional 39,540 shares in the last quarter. Greenhouse Funds LLLP lifted its position in shares of Phreesia by 16.8% during the 3rd quarter. Greenhouse Funds LLLP now owns 3,882,527 shares of the company’s stock valued at $91,317,000 after buying an additional 557,265 shares in the last quarter. Granahan Investment Management LLC lifted its position in shares of Phreesia by 73.8% during the 4th quarter. Granahan Investment Management LLC now owns 2,399,613 shares of the company’s stock valued at $40,601,000 after buying an additional 1,018,987 shares in the last quarter. Franklin Resources Inc. grew its stake in Phreesia by 28.8% in the 4th quarter. Franklin Resources Inc. now owns 2,000,082 shares of the company’s stock valued at $33,841,000 after acquiring an additional 446,890 shares during the period. Finally, Nuveen LLC grew its stake in Phreesia by 12.7% in the 4th quarter. Nuveen LLC now owns 1,875,725 shares of the company’s stock valued at $31,737,000 after acquiring an additional 211,262 shares during the period. 92.10% of the stock is currently owned by hedge funds and other institutional investors.

Key Stories Impacting Phreesia

Here are the key news stories impacting Phreesia this week:

• Positive Sentiment: Quarter results showed revenue growth and improved cash generation, with management flagging free cash flow and adjusted EBITDA milestones reached — evidence the business is profitable and generating cash. Business Wire: Phreesia Announces Fourth-Quarter Fiscal 2026 Results
• Neutral Sentiment: Several firms reaffirmed neutral/hold ratings but cut price targets, reflecting mixed conviction — e.g., JPMorgan (neutral, PT $16 from $24), Robert W. Baird (neutral, PT $10 from $25), Citigroup (neutral, PT $10 from $25), and Truist (hold, PT $11 from $24). These actions compress near-term upside expectations even where conviction remains. Benzinga: Why Is Phreesia Stock Sinking Tuesday?
• Negative Sentiment: Management cut FY27 revenue guidance to $510–$520M (from $545–$559M), citing reduced visibility into pharma client spending and weaker second-half commitments — the primary catalyst for the selloff and for multiple analyst downgrades/price-target reductions. Benzinga: Guidance cut explained
• Negative Sentiment: Major brokers sharply trimmed targets and/or ratings (examples: Stephens cut PT to $20 but kept overweight; BMO to $14/outperform; Canaccord to $22/buy; Needham to $14/buy), increasing near-term downside pressure despite some upbeat long-term views. Benzinga: Analyst price target updates
• Negative Sentiment: Market reaction: shares plunged and hit fresh lows on the guidance cut with unusually high volume, signaling broad investor de-risking and driving further volatility. MarketWatch: Shares touch all-time lows

About Phreesia

Phreesia, Inc (NYSE: PHR) is a provider of patient intake management solutions designed to streamline front-office workflows for healthcare organizations. The company’s cloud-based platform digitizes patient registration, appointment scheduling, insurance verification, consent documentation and payment collection through touchscreen kiosks, tablets and mobile devices. By replacing paper forms and manual processes, Phreesia enhances data accuracy, reduces administrative burden and improves the patient experience.

Founded in 2000 by Chaim Indig and headquartered in Burlington, Massachusetts, Phreesia offers a modular software suite that integrates with electronic medical record (EMR) and practice management systems.